Altered insulin sensitivity, insulin secretion and lipid profile in non-diabetic prostate carcinoma

Acta Physiologica Hungarica

Volumn 95, Issue 1, 2008, Pages 97-105

  Nandeesha, D H ^a   Koner, B C ^a   Dorairajan, L N ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Hyperinsulinemia; Insulin sensitivity; Lipid profile; Prostate carcinoma

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERINSULINISM; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATE TUMOR;

AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FASTING; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRIGLYCERIDES;

EID: 40049096126     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.95.2008.1.7     Document Type: Article

References (40)

1. Underwood W, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, Wood DP: Racial treatment trends in localized regional prostate carcinoma: 1992-1999. Cancer 103(3), 538-545 (2005)
2. Sharma S, Nath P, Srivastava AN, Singh KM: Tumors of the male urogenital tract: A clinicopathologic study. J. Indian Med. Assoc. 92(11), 357-360 (1994)
3. Nagpal BL, Prabhakar BR, Kataria SP, Kapoor K, Bal MS: Male genital tract tumors in Punjab, India. J. Environ. Pathol. Toxicol. Oncol. 11(5-6), 331-334 (1992)
4. Debas JD, Tindall DJ: The role of androgens and the androgen receptor in prostatecancer. Cancer Lett. 187(1-2), 1-7 (2002)
5. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Ribole E, Hallmans G, Kaaks R: Plasmainsulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J. Natl. Cancer Inst. 92(23), 1910-1917 (2000)
6. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 17(4), 337-347 (1990)
7. Elghany NA, Schumacher MC, Slattery ML, West DW, Lee JS: Occupation, cadmium exposure and prostate cancer. Epidemiology 1(2), 107-115 (1990)
8. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovanucci EL, Stampfer MJ: Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl, Cancer Inst. 86(4), 281-286 (1994)
9. Kaaks R: Plasma insulin, IGF-I and breast cancer. Gynecol. Obstet. Fertil. 29(3), 185-191 (2001)
10. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J. Nutr. 31, 3109S-3120S (2001)
11. Mckeehan WL, Adams PS, Rosser MP: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin but not androgen on normal rat prostate epithelial cells in, serum-free primary cell culture. Cancer Res. 44, 1998-2010 (1984)
12. Carmena MJ, Fernandez-Moreno MD, Prieto JC: Characterization of insulin receptors in isolated epithelial cells of rat ventral prostate. Effect of fasting. Cell. Biochem. Fun. 4, 19-24 (1986)
13. Nandeesha H, Koner BC, Dorairajan LN, Sen SK: Hyperinsulinemia and dyslipidemia in non diabetic benign prostatic hyperplasia. Clinica Chemiea Acta 370, 89-93 (2006)
14. Hammarsten J, Hogstedt B: Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 39, 151-158 (2001)
15. Gungor N, Saad R, Janosky J, Arslanian S: Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J. Pediatr. 144, 47-55 (2004)
16. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik HY, Lee C: A high-risk group for prostatism: A population-based epidemiological study in Korea. Br. J. Urol, 79, 736-741 (1997)
17. Tchernof A, Laraarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP: The dense LDL phenotype association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19, 629-637 (1996)
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985)
19. Katz A1 Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402-2410 (2000)
20. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18(6), 499-502 (1972)
21. Hammarsten J, Hogstedt B: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 13(1), 47-55 (2004)
22. Hammarsten J, Hogstedt B: Hyperinsulinemia: A prospective risk factor for lethal clinical prostate cancer. Eur. J. Cancer 41(18), 2887-2895 (2005)
23. Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J. Urol. 162, 293 (1999)
24. Haffner SM: Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: Epidemiological and clinical correlation. Int. J. Obes. Relat. Metab. Disord. 24, S56 (2000)
25. Hautanen A: Synthesis and regulation of sex hormone-binding globulin in obesity. Int. J. Obes. Relat. Metab. Disord. 24, S64 (2000)
26. Peehl DM, Cohen P, Rosenfeld RG: The role of insulin-like growth factors in prostate biology. J. Androl. 17, 2-4 (1996)
27. McCarty MF: Upregulation of IGF binding protein-1 as an anticarcinogenic strategy: Relevance to caloric restriction, exercise and insulin sensitivity. Med. Hypotheses 48, 297-308 (1997)
28. Pollak M, Beamer W, Zhang JC: Insulin like growth factors and prostate cancer. Cancer Metastasis Rev. 17, 383-390 (1998-1999)
29. Shpakov AO, Plesneva SA, Kuznetsova LA, Pertseva MN: Study of the functional organization of a novel adenylate cyclase signaling mechanism of insulin action. Biochemistry (Mose). 67, 335-342 (2002)
30. Pertseva MN, Shpakov AO, Plesneva SA, Kuznetsova LA: A novel view on the mechanisms of action of insulin and other insulin superfamily peptides: Involvement of adenylyl cyclase signaling system. Comp. Biochem. Physiol, B. Biochem. Mol. Biol, 134, 11-36 (2003)
31. Moorjani S, Dupont A, Labrie F: Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: Effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J. Clin. Endocrinol. Metab. 66(2), 314-322 (1988)
32. Bagateli CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ: Physiologic testosterone levels in normal men suppress HDL-cholesterol levels. Annals of Internal Medicine. 116, 967-973 (1992)
33. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Relation of high TG - low HDL-cholesterol and LDL-cholesterol to the incidence of ischemic heart disease. An 8 year follow-up in the Copenhagen Male study. Arterioseler. Thromb. Vase. Biol. 17(6), 1114-1120 (1997)
34. Fossati P, Romon-Rousseaux M: Insulin and HDL-cholesterol metabolism. Diabet. Metab. 13, 390-394 (1987)
35. Ginsberg HN, Ngai C, Wang XJ, Ramakrishnan R: Increased production rates of LDL are common in individuals with low plasma levels of HDL-cholesterol independent of plasma triglyceride concentrations. Arterioseler. Thromb. 13, 842-851 (1993)
36. Kondo A, Li J, Manabe M, Saito K, Kanno T, Maekawa M: Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J. Atheroseler. Thromb. 10, 72-78 (2003)
37. Biwa T, Sakai M, Shichiri M, Horiuchi S: Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized low density lipoprotein-induced macrophage proliferation. J. Atheroseler. Thromb. 7, 14-20 (2000)
38. Pai R, Kirschenbaum MA, Kamanna VS: Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int. 48, 1254-1262 (1995)
39. Mollers C, Drobnik W, Resnik T, Schmitz G: High-density lipoprotein and low-density lipoprotein mediated signal transduction in cultured human skin fibroblasts. Cell Signal 7(7), 695-707 (1995)
40. Sakai M, Kobori S, Miyazaki A, Horiuchi S: Macrophage proliferation in atherosclerosis. Curr. Opin. Lipidol. 11(5), 503-509 (2000)